Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Medlmmune's 'wild card' backfires

MedImmune Inc. said that Wall Street misinterpreted its decision to end its clinical program for the treatment of respiratory syncytial virus, after investors drove the company's stock down 47 percent to $4.875 last week.

The company announced it was ending the program after reviewing the results of

Read the full 469 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers